ArticleHepatology communications2020
Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta-Analysis.
Article in Hepatology communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 3 syntheses or guidelines pooled it, 155 citations in OpenAlex.
- Pooled it
- AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.Gastroenterology · 2022Guideline
- Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.BMC gastroenterology · 2021Pooled it
- Predictors of metabolic dysfunction-associated steatotic liver diseases (MASLD) in Vietnamese population.Scientific reports · 2026Article
- Metabolic characteristics and risk profile of non-obese fatty liver disease in an elderly Chinese community cohort.BMC gastroenterology · 2026Article
- From Childhood to Old Age: Current Knowledge and Practical Approaches to Metabolic Dysfunction-Associated Steatotic Liver Disease.Journal of clinical medicine · 2026Review
- Steatosis-Associated Fibrosis Estimator Score in Asian Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.Yonsei medical journal · 2026Article
- Dysregulated high-density lipoprotein and low-density lipoprotein subfractions increase metabolic dysfunction-associated steatotic liver disease risk: a study of patients across body mass index categories.Frontiers in nutrition · 2026Article
- Influence of Metabolic Dysfunction-Associated Steatotic Liver Disease on Pattern and Management of Acute Coronary Syndrome.Saudi medical journal · 2026Article
- Predictors of Metabolic Dysfunction-Associated Steatotic Liver Diseases (MALSD) in Vietnamese Population.Research square · 2025Article
- CUN‑BAE predicts risk of metabolic dysfunction-associated steatotic liver disease: A prospective cohort study in non‑obese Chinese adults.Scientific reports · 2025Article
- Cross-ancestry discovery of genetic risk variants for lean metabolic dysfunction-associated steatotic liver disease.Cell & bioscience · 2025Article
- Clinical and Genetic Predictors of Non-Alcoholic Steatotic Liver Disease and Fibrosis in Lean Individuals.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Association of lean metabolic dysfunction-associated steatotic liver disease with carotid plaque progression in patients with type 2 diabetes mellitus.Journal of diabetes investigation · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention.International journal of molecular sciences · 2025Review
- [Research progress on clinical characteristics and pathological mechanisms of lean metabolic-associated fatty liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- Association Between High-Sensitivity C-Reactive Protein Levels and Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis Risk: A Study Based on NHANES Data.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Effect of lean status on the mortality of patients with non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis.Pakistan journal of medical sciences · 2025Review
- Clinical characteristics and risk factors of metabolic dysfunction-associated steatotic liver disease in lean patients: results of the Polish Gallstone Surgery Registry.Clinical and experimental hepatology · 2025Article
- Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk.BMC gastroenterology · 2025Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data on prevalence and profile of nonalcoholic fatty liver disease (NAFLD) among individuals who are lean (normal body mass index) is unclear. Published data from studies comparing lean with obese NAFLD or with healthy subjects on prevalence, comorbidities, liver chemistry and histology, and metabolic/inflammatory markers were analyzed. Data were reported as odds ratio and 95% confidence interval for categorical variables and difference of means for continuous variables. Analysis of 53 studies on 65,029 subjects with NAFLD (38,084 lean) and 249,544 healthy subjects showed a prevalence of lean NAFLD at 11.2% in the general population. Among individuals with NAFLD, the prevalence of lean NAFLD was 25.3%. Lean NAFLD versus healthy subjects had higher odds for abnormalities on metabolic profile, including metabolic syndrome and its components, renal and liver function, and patatin-like phospholipase domain-containing protein 3 (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.